Op-Eds
New Drug Demagoguery
“New Drugs Hit the Market, but Promised Trials Go Undone” and “FDA: Drug Companies Drop Ball on Studies,” the headlines blared.
Op-Eds
Patients vs. Paternalism
Decisions about drug safety and efficacy are far from easy. Tysabri, a multiple sclerosis (MS) drug that was voluntarily withdrawn from the market last year…
Op-Eds
The Lancet Pricks Itself
The term “medical journals” elicits automatic respect from most people. Not from me: I read them. I've found the editors to be increasingly…
Op-Eds
WTO and Biotech Food: Who Really Won?
The long-awaited World Trade Organization decision on biotechnology applied to agricultural products, finally released earlier this month, elicited a great deal of buzz…
Op-Eds
In the Interests of Stakeholders… and Steakholders
There was good news last month on both sides of our northern border: In response to confirmation of an isolated case of bovine…
Op-Eds
All the news that fits
Newspapers are often criticized for bias in their “news” articles. A prime example was Andrew Pollack's Feb. 14 New York Times piece on…